MDM2 and ovarian cancer: MDM2, a novel non‐histone substrate of hMOF, directly interacts with hMOF, leading to MDM2 acetylation, which inhibits its ubiquitination and degradation, thereby increasing MDM2 stability and enhancing cisplatin resistance in ovarian cancer cells.60